CJC-1295 Research DEXA Scan Notes

In research documentation, "DEXA scan notes" attached to CJC-1295 work refer to body composition data — fat mass, lean soft tissue, and bone mineral content — captured by dual-energy X-ray absorptiometry and logged as a measured endpoint in laboratory investigations of growth hormone–releasing hormone (GHRH) analogs. They are a record of what an instrument measured under a stated procedure, not evidence of a human benefit, a treatment result, or anything a business should repeat to a customer as a claim. CJC-1295 is a research compound, and Real Peptides supplies CJC-1295 No DAC 10mg on a research-use-only basis.

If you are a med spa operator, clinic owner, telehealth founder, or reseller evaluating this compound for your catalog, the scan itself is rarely the part that should influence your purchasing decision. The part that should is the documentation chain sitting underneath it — what material was used, who tested it, what method was used to test it, and whether you can look at that result yourself. This article covers what the imaging endpoint actually measures, why it recurs in growth hormone axis literature, what a complete research note contains, and how to read a supplier's paperwork before you read anyone's data.

What dual-energy X-ray absorptiometry actually measures

DEXA is an imaging technique that passes X-ray energy at two distinct levels through a body or sample and derives composition from how differently the two beams are attenuated. The output is conventionally split into three compartments: bone mineral content, lean soft tissue, and fat mass. Most instruments also generate regional breakdowns — trunk, limbs, and in some configurations an estimate of visceral versus subcutaneous adipose distribution — rather than a single whole-body figure.

Two practical characteristics explain why researchers reach for it. First, it is non-destructive and repeatable, so the same subject can be scanned at multiple timepoints and compared against its own baseline. Second, its precision for distinguishing lean from fat compartments is generally better than circumference measurements or bioimpedance, which makes it a reasonable instrument when a study needs to detect a change in tissue distribution rather than a change in total mass.

It is not a universal measuring tool. DEXA output depends on machine calibration, software version, positioning, and hydration state of the subject, and results from different instruments are not freely interchangeable. That is precisely why a rigorous scan note documents the machine, the calibration phantom, the software build, and the operator — and why a note that says only "DEXA performed" is not a note at all.

Why body composition endpoints recur in growth hormone axis literature

CJC-1295 is a synthetic analog of growth hormone–releasing hormone, structurally derived from the GHRH(1-29) fragment with substitutions intended to slow enzymatic degradation. The version without the drug affinity complex, commonly written as CJC-1295 No DAC or modified GRF(1-29), lacks the conjugation that extends circulating presence in the DAC form. Research interest in these molecules centers on the signaling cascade — GHRH receptor engagement, downstream growth hormone release from the pituitary, and IGF-1 as a measurable secondary marker.

Body composition is a downstream, observable consequence of that axis, which is why investigators studying GHRH analogs and related secretagogues have reported composition endpoints alongside biochemical ones. Studies in this area generally report hormonal markers as the primary readout and use imaging as a corroborating measure. Research on the broader class suggests the axis influences how the body partitions lean and adipose tissue, but the literature is uneven in quality, heavily weighted toward animal and in-vitro models, and frequently confounded by differences in study design, analog form, and measurement method.

The honest summary for a business buyer is this: imaging endpoints appear in the literature because they are a convenient way to capture a downstream signal, not because any of it establishes a result you can promise. Treat the presence of DEXA data in a paper as a methodological detail, not as a marketing asset.

What a complete research note should contain

A scan note that supports any interpretation at all includes more than the numbers. At minimum, a usable record documents the instrument and its calibration status, the scan date and the interval from baseline, the subject or sample identifier, the software and analysis mode used, and the operator. Without those, two scans cannot be meaningfully compared, and a claimed change may be an artifact of a software update.

The element that most often goes missing is the one a wholesale buyer should care about most: the compound record. A defensible note identifies the exact material used, including the supplier, the lot or batch number, the stated purity, and the analytical method that established it. When a research file says "CJC-1295" with no lot reference and no certificate of analysis, the entire downstream dataset rests on an unverified assumption about what was in the vial.

This is not an abstract concern in the research peptide market. Identity and purity vary between suppliers and between batches from the same supplier, and a compound that is 90 percent target molecule with an uncharacterized remainder is not the same input as one verified at high purity by a stated method. Any data generated from unverified material is interesting at best and misleading at worst.

Reading the certificate before you read the data

For a buyer building a catalog, the practical skill is not interpreting scan output — it is interpreting supplier documentation. The table below maps the documentation elements worth demanding against what each one establishes and the gap to watch for.

Industry practices worth avoiding are consistent and easy to spot. Pricing that appears only after a sales call. Certificates held behind a request form or billed separately. Testing described as independent without a laboratory ever being identified. Batch numbers that do not reconcile with the certificate you were sent. None of these prove misconduct on their own, but each removes a verification step you would otherwise have, and a buyer who accepts all four has no verification left.

Regulatory questions to take to your attorney and state board

This section is informational and is not legal advice. The regulatory position of research-use-only compounds is genuinely unsettled in places and varies by jurisdiction, business structure, and what a business actually does with the material, so the correct output here is a list of questions rather than a set of conclusions.

Worth resolving with your own counsel and, where relevant, your state licensing board: How does your jurisdiction characterize the resale and distribution of research-use-only materials, and does that characterization change based on your license type? What registrations, permits, or facility requirements might apply to your specific business model? How must research-use-only material be labeled, stored, and described in your marketing, and what claims are off-limits? What recordkeeping does your jurisdiction expect around lot traceability and supplier documentation? If your business model spans multiple states, which rules follow the buyer and which follow the seller?

General principles that hold across most contexts: research-use-only compounds are not FDA-approved drugs, they are not represented as safe or effective for human use, and describing them in therapeutic terms is the fastest way to create a problem for your business. The specifics belong with your attorney, not with a supplier's blog post.

What Real Peptides does differently

Real Peptides publishes purity and testing documentation rather than describing it. Catalog compounds are produced to 99%+ HPLC purity, and every batch runs through a seven-panel batch testing program before release. The resulting certificates of analysis are publicly verifiable — a prospective partner can check the lab results directly rather than requesting them through a sales representative or paying for access, which means the verification step described earlier in this article is available before the first order rather than after it.

Fulfillment is US-based, with orders shipping within five to seven days. Wholesale access runs through a three-step application to the Wholesale Partner Program, and tiered pricing is presented as part of that process rather than withheld behind a discovery call. All compounds, CJC-1295 included, are supplied for research use only. Real Peptides does not provide dosing, reconstitution, preparation, or administration guidance for any compound in the catalog, because that guidance has no place in a research-use-only supply relationship — what the company does provide is the concentration framework on the label, expressed as milligrams per vial, and the analytical documentation behind it.

Where this leaves a buyer evaluating the compound

If you are assessing CJC-1295 for a wholesale catalog, the imaging literature is context, not justification. Scan endpoints tell you what instrument a researcher used and what compartments they tracked; they tell you nothing about the material in the vial you are about to buy, and they tell you nothing you can pass along as a claim. The decision that actually matters is upstream — whether your supplier can show you, before you commit, exactly what is in each batch and who verified it.

If your business can operate cleanly within research-use-only framing and you have your own compliance position settled with counsel, the Wholesale Partner Program application is the next step. It takes three steps, pricing tiers are disclosed as part of it, and the certificates you would be relying on are already public for you to review beforehand.

For related research context, Real Peptides also publishes documentation for compounds studied alongside GHRH analogs in the same signaling literature, including Ipamorelin 10mg and Tesamorelin 10mg, and maintains a broader growth factor and tissue signaling research collection as well as a popular peptides catalog with the same purity and batch testing standards applied across every listing.